LIFETECH SCI.DL-00000125 Total Liabilities

Latest as of December 2025: €1.54 Billion EUR ≈ $1.80 Billion USD

LIFETECH SCI.DL-00000125 total liabilities. Based on the latest financial reports, LIFETECH SCI.DL-00000125 (81X) has total liabilities worth €1.54 Billion EUR (≈ $1.80 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 81X asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of LIFETECH SCI.DL-00000125 (2021–2025)

Total liabilities of LIFETECH SCI.DL-00000125 from 2021 to 2025. This chart illustrates how LIFETECH SCI.DL-00000125's total liabilities have evolved over time, based on quarterly financial data.

LIFETECH SCI.DL-00000125 Competitors by Total Liabilities

The table below lists competitors of LIFETECH SCI.DL-00000125 ranked by their total liabilities.

Company Country Total Liabilities
Gujarat Pipavav Port Limited
NSE:GPPL
India Rs6.35 Billion
Wuzhou Special Paper Group Co. Ltd.
SHG:605007
China CN¥9.64 Billion
Tongyang Inc
KO:001525
Korea ₩616.60 Billion
Santacruz Silver Mining Ltd.
V:SCZ
Canada CA$277.09 Million
Nantong Jinghua Pharmaceutical Co Ltd
SHE:002349
China CN¥386.24 Million
PARATUS ENERGY SERVICES LTD
OL:PLSV
Norway Nkr778.90 Million
Mirae Asset Daewoo Co Ltd Pref
KO:00680K
Korea ₩131.83 Trillion
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
China CN¥7.52 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down LIFETECH SCI.DL-00000125's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LIFETECH SCI.DL-00000125 balance sheet assets.

Liquidity & Leverage Metrics

LIFETECH SCI.DL-00000125 Total Liabilities Ratios Explained

LIFETECH SCI.DL-00000125 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.57 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.44 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how LIFETECH SCI.DL-00000125's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for LIFETECH SCI.DL-00000125 (2021–2025)

The table below shows the annual total liabilities of LIFETECH SCI.DL-00000125 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €1.54 Billion
≈ $1.80 Billion
+7.89%
2024-12-31 €1.42 Billion
≈ $1.67 Billion
+3.83%
2023-12-31 €1.37 Billion
≈ $1.60 Billion
+78.45%
2022-12-31 €769.05 Million
≈ $899.10 Million
+17.66%
2021-12-31 €653.61 Million
≈ $764.14 Million
--

About LIFETECH SCI.DL-00000125

F:81X Germany Medical Devices
Market Cap
$848.92 Million
€726.13 Million EUR
Market Cap Rank
#9293 Global
#1177 in Germany
Share Price
€0.17
Change (1 day)
+7.14%
52-Week Range
€0.13 - €0.23
All Time High
€0.47
About

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac P… Read more